Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development.

111 , 112 However, there are mixed results in human LF cases treated with convalescent plasma (~3–4 ml/kg), and it has been suggested geographic matching of convalescent plasma, as well as titers of neutralizing antibodies per therapeutic dose, may be significant factors in effective passive therapy. 69 , 73 , 113 , 114 A guinea pig animal model has indicated the degree of protection and in vivo suppression of LASV may be closely associated with neutralization ability (via PRNT and LNI). 69 , 70 Additionally, there are concerns that the level of neutralizin

also in 13,097 other papers

15 Overall, there has not been any analysis of economic burden attributed to LF, but given the estimated annual incidence of disease per year; it is likely to be significant in endemic areas of Africa.

also in 1,824 other papers